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1. Introduction 
Coronary artery disease remains highly prevalent in contemporary society and over 1000000 
revascularisation procedures by percutaneous coronary intervention (PCI) are performed 
annually worldwide. PCI has seen significant improvement in clinical outcomes with the 
current generation of drug eluting stents. The role of PCI in multivessel coronary disease 
has been expanded with current trial evidence indicating equipoise between PCI and 
coronary artery by-pass surgery in selected groups. 
Increasingly, coronary artery by-pass surgery (CABG) or PCI is being considered as an 
equivalent revascularisation strategy within the same patient population. Given the options 
available to clinicians and patients it is important to have robust tools to accurately compare 
the risk and benefits of selected strategies when making management decisions. Whilst these 
tools have been available to the cardiac surgeons for some time (Granton & Cheng, 2008), an 
equivalent tool for the interventional cardiologist has only recently been published. 
The CANADA Score is a risk prediction model for determining 30 day mortality risk in 
patients undergoing elective, urgent and emergent PCI. Its development and validation will be 
discussed with reference to the established cardiac surgical risk calculators currently available. 
2. Risk prediction models 
Risk prediction models are statistical models produced from patient databases using a 
combination of individual risk predication markers and are used by clinicians and patients 
for making treatment decisions. Model inaccuracy and ineffectiveness can therefore have 
negative implications on risk measurement and subsequent patient decisions and outcomes. 
The accuracy of the model is typically summarised in terms of the model’s discrimination 
and calibration (Janes et al, 2008). The applicability of a risk model to a patient population is 
determined by validation. 
2.1 Discrimination 
Discrimination is the ability of the model to correctly classify outcomes (Nathanson & 
Higgins, 2008). The statistical measures of area under the curve (AUC) or concordance index 
(C-index) are commonly used to describe how well patients are classified within the model. 
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Patients typically are assigned a positive classification if the model predicts the probability 
of an outcome as >0.5. Conversely, a negative classification indicates the model predicts the 
probability of an outcome is <0.5. A patient is therefore correctly classified when an 
outcome event occurs in a patient with a positive classification, or when no event occurs in a 
patient with a negative classification. Sensitivity and specificity are derived from the fraction 
of correctly classified patients. The receiver operating characteristic (ROC) curve is derived 
from the plot of specificity against (1 – sensitivity), and the area under the ROC curve (AUC) 
measures the discriminatory ability of the model. An AUC of 0.5 indicates no discriminatory 
ability and 1.0 indicates perfect discrimination (Cook, 2008). A good model would have 
AUC 0.7 – 0.9. 
2.2 Calibration 
Calibration is determined by comparing the predicted and observed outcomes within 
subgroups of increasing risk within the dataset and applying the Hosmer-Lemeshow (H-L) 
statistical test (Hosmer & Lemeshow, 2000) to assess “goodness of fit”. The H-L goodness of 
fit test divides subjects into deciles based on predicted probabilities and calculates a chi-
square from observed and expected frequencies. If the H-L statistic has p-value >0.05, it 
implies there is no significant difference between observed and model-predicted values and 
therefore the model is well calibrated. Calibration plots can be used to give a graphical 
representation of model calibration. 
2.3 Validation 
Strategies to validate statistical models include (Altman & Royston, 2000): 
a. Internal – evaluation from a single dataset 
Internal validation refers to the application of a model to the same cohort from which it 
was derived, often by splitting one dataset into separate training and validation cohorts. 
This can be problematic as models tend to over fit the data and calibration appears 
erroneously good (Vickers & Cronin, 2010). Internal validation also does not address 
real differences that may exist between different cohorts. Methods to improve internal 
validation include cross validation and bootstrap resampling. 
b. Temporal – evaluation of a second dataset after the original cohort 
Temporal validation involves collecting data from the same sources but at a later time 
point. It is a prospective evaluation of the original model, but it may take considerable 
time to accrue an adequate number of events in the second dataset. 
c. External – evaluation of geographically separate cohorts  
External validation addresses the generalizability of the statistical model by application 
to a different population from that used to derive the model. It can be performed 
retrospectively making it attractive for widespread application and can help address 
issues related to sample selection. 
3. Cardiac surgical models 
3.1 STS score 
The Society of Thoracic Surgeons (STS) National Adult Cardiac Database was established in 
1989 and currently contains over 4.5 million records. It represents >90% of adult cardiac 
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surgical procedures performed in the United States. In the interval 1997-1999 there were 503 
478 CABG-only procedures identified from 495 participating centres. From this, 30 potential 
risk factors for mortality were identified on univariate screening (Table 1). The over-all 30 
day mortality rate was 3.05%. Using multivariate logistic regression an STS Score model was 
developed that had good discrimination (c-index 0.78) and modest calibration (H-L p = 
0.0016) (Table 2) (Shroyer et al, 2003). 
3.2 EuroSCORE 
A European multi-national database was established in 1995 (Nashef et al, 1999) and 
information on risk factors and mortality was collected for 19 030 consecutive adult patients 
undergoing cardiac surgery under cardiopulmonary bypass in 128 surgical centres in eight 
European states (Roques et al, 2003). Data were collected for 68 preoperative and 29 
operative risk factors proven or believed to influence mortality. From this a series of 
objective risk factors (Table 1) were weighted by regression analysis and developed into an 
additive score (additive EuroSCORE) to predict mortality. Overall, 14 799 patients were 
divided into a developmental cohort (n= 13 302) and validation cohort (n= 1479). The 30 day 
mortality was for the entire cohort was 4.7%. The additive EuroSCORE had good 
discrimination in both the development (c-index 0.79) and validation (c-index 0.76) cohort, 
as well as good calibration (H-L p value <0.40 & <0.68 respectively) (Table 2). The additive 
EuroSCORE was further externally validated in a North American population. Despite 
demographic differences the model performed well with discriminatory c-index 0.75 and 
excellent calibration (predicted and observed mortality 4.15%) (Nashef et al, 2002). 
A limitation of the additive EuroSCORE was underestimation of risk in very high risk 
populations (Sergeant et al, 2001). A second model was published using the coefficient of the 
variables in the logistic regression data rather than additive weights to predict mortality. 
The logistic EuroSCORE had similar discrimination (c-index 0.785) to the additive model but 
superior accuracy in high risk populations. The models diverged at a predicted mortality of 
8-10% (Michel et al, 2003). 
 
 STS Score EuroSCORE CANADA Score 
Patient Factors    
Age X X X 
Gender X X X 
Renal failure X X X a 
Critical preoperative state X X X 
Chronic lung disease X X  
PVD / CVD X X  
CVA / Neurological 
dysfunction 
X X  
Previous cardiac surgery X X  
Multiple reoperations X   
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 STS Score EuroSCORE CANADA Score 
Ethnicity X   
BSA X   
Diabetes X   
Hypercholesterolemia X   
Hypertension X   
Immunosuppressive Rx X   
Smoker X   
Cardiac-Related Factors  
Aortic stenosis X  X b 
LV dysfunction (LVEF) X X X 
NYHA IV X X X 
IABP X X X c 
LMS X  X 
Triple vessel disease X  X 
Current ACS   X 
STEMI recurrent / on-
going 
  X 
Prior MI X X  
PTCA <6 hrs X   
Mitral insufficiency X   
Active endocarditis  X  
Pulmonary hypertension  X  
Operation Related Factors  
Urgent status X X X 
Other than isolated CABG  X  
Surgery on thoracic aorta  X  
Post infarct septal rupture  X  
a, Dialysis; b, Contraindications to left ventricular contrast angiography include 
significant aortic stenosis (valve area <1.0 cm2); c, Critical pre-procedure state includes 
the anticipated need for IABP 
Table 1. Comparison of Risk Factors Used to Predict 30-Day Mortality in Various Models. 
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Model Patients 30 day mortality C-Index H-L p-value 
STS Score development  503478 3.05% 0.78 .0016 
Additive EuroSCORE 
development 
13302 4.7% 0.783 <0.40 
Additive EuroSCORE 
validation 
1497 4.7% 0.76 <0.68 
Logistic EuroSCORE 14799 4.7% 0.785 N/A 
CANADA Score training set 
(development) 
26350 1.5% 0.90 0.84 
CANADA Score validation 6549 1.4% 0.91 0.12 
NCDR CathPCI Risk Score 
subset 
204111 2.94% 0.86 N/A 
Table 2. Comparison of Cohort and Model Performance for Various Risk Calculators. 
4. PCI models 
Early models examining risk associated with percutaneous coronary interventions were well 
validated for the predication of in-hospital mortality ( Moscucci et al, 2001; Qureshi et al, 
2003; Resnic et al, 2001; Shaw et al, 2002; Singh et al, 2002; Wu et al, 2006). However, these 
models had the potential to miss adverse events due to the nature of contemporary PCI 
where many patients are discharged within 24 hours of admission. As patients may be 
suitable for revascularization by either CABG or PCI it was important to develop a tool to 
facilitate an appropriate comparison of outcomes between these strategies. 
4.1 NCDR CathPCI risk score 
Contemporary risk scores were developed from the National Cardiovascular Data Registry 
(NCDR) (Peterson et al, 2010). The NCDR CathPCI Registry catalogues patient 
characteristics, angiographic and procedural details and in-hospital outcomes. From this, 
various risk models to predict in-hospital mortality were derived from pre-procedural and 
procedural data (full model), as well as a simplified model based on pre-procedure data 
only. To establish 30-day mortality, the NCDR records for patients aged over 65 were linked 
to claims data from the national Centers for Medicare and Medicaid Services (CMS). Linked 
data from 204111 patients observed in-hospital mortality as 1.99% and 30 day mortality as 
2.94%. The c-index for predicating 30-day mortality using the NCDR in-patient mortality 
model was 0.86. 
5. The CANADA score 
The British Columbia Cardiac Registry (BCCR) is a population based database for all 
invasive cardiac procedures performed in British Columbia, Canada. The registry is used for 
clinical, administrative and research purposes. The linkage of BCCR data with the death 
registry of the British Columbia (BC) Vital statistics Agency facilitates outcome research. All 
procedures were performed at four academic tertiary centres that collectively perform 7500 
PCI annually. 
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All patients who had PCI performed in British Columbia (BC) from 2000 – 2005 who were 
BC residents were included in the study (Hamburger et al, 2009). PCI was defined as any 
coronary artery procedure that included balloon angioplasty, stent implantation, 
atherectomy, brachytherapy and thrombectomy. Second or subsequent PCI were not 
included for further analysis. All cause mortality data was obtained from the BC Vital 
Statistics Agency.  
The study cohort was divided into two groups. Procedures between January 01, 2000 and 
December 31, 2004 formed the training set that was used to develop the multivariable 
predictive model for all-cause 30-day mortality. Procedures from 2005 were used to validate 
the model. 
Variables for predicting 30-day mortality post PCI included patient demographics, co-
morbidities and clinical features such as indication for procedure and disease anatomy. 
Variables that were significantly associated with 30-day mortality in the univariate analysis 
(Table 3) or that were considered to be clinically important predictors for 30-day mortality 
were assessed in a stepwise logistic regression analysis. Only significant predictors (P < 
0.05) in the multiple logistic regression analysis were kept in the final predictive model 
(Table 4). 
A total of 32 899 procedures were performed. These were divided into 26 350 in the training 
set and 6549 in the validation set. The overall 30-day mortality was 1.5% (n=500), with 
mortality in the training set 1.5% (n=406) and validation set 1.4% (n=94) respectively.  Of 
note, overall approximately one third of deaths occurred beyond 7 days (161/500, 32.2%) 
with similar proportions in the training (121/406, 29.8%) and validation sets (40/94, 42.6%) 
(Figure 1). The discrimination of the CANADA Score was good with the c-index for the 
training set 0.90 (Figure 2) and 0.91 for the validation set (Figure 3). The calibration was also 
good (H-L p values 0.84 & 0.12 respectively) (Table 2). 
 
Fig. 1. Cumulative mortality versus time for all deaths in CANADA Score study population. 
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Fig. 2. Receiver operator characteristic (ROC) curve for CANADA Score training set. 
 
Fig. 3. Receiver operator characteristic (ROC) curve for CANADA Score validation set. 
The CANADA Score was further externally validated using data sets from Alberta, Canada, 
and Massachusetts, United States of America. 
The Alberta Provincial Project for outcome Assessment in Coronary Heart Disease 
(APPROACH) began 15 years ago as a cardiac catheterization and cardiac surgery database. 
The database includes clinical information on 126,500 patients with diagnostic cardiac 
catheterization and/or revascularization procedures, and 34000 hospital admissions for ACS 
(www.approach.org). The Canada Score model was evaluated against 9483 PCI performed 
from April 2005 – March 2008. The 30-day mortality was 1.8%. The c-index for this cohort 
was 0.88 (Kurana et al, 2010a). 
The Massachusetts Department of Public Health began collecting patient specific outcome 
data to evaluate all cardiac surgery and coronary intervention programs in 2002. Data were 
submitted to the Massachusetts Data Analysis Center (Mass-DAC) with data collection for 
coronary interventions using the ACC-NCDR Instrument beginning in 2003 
(www.massdac.org). During the period Jan 2005 – September 2007, 36 341 PCI procedures 
were performed. The 30-day mortality was 2.05% and c-index for the Canada Score in this 
cohort was 0.87 (Kurana et al, 2010b). 
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Category 
Number of 
patients 
Number 
of deaths
30-Day 
mortality 
rate (%) 
Odds 
ratio 
95% 
Confidence 
intervals 
P 
Total number of 
patients 
26,350 406     
Age (continuous) 
Mean ± SD: 64.3 ± 
11.5 
26,350   1.05 1.04–1.06 <0.001 
Gender       
 Male 19,283 265 1.37 1.00 Ref.  
 Female 7,064 141 2.00 1.46 1.19–1.80 <0.001 
Urgency of 
procedure 
      
 Non-urgent 7,626 219 0.18 1.00 Ref.  
 Emergency 2,965 171 7.39 43.36 25.22–74.56 <0.001 
 Urgent 15,643 14 1.09 6.01 3.48–10.37 <0.001 
Extent of 
coronary artery 
disease 
      
 Single or two 
vessel disease 
17,420 176 1.01 1.00 Ref.  
 Triple-vessel 
disease 
7,830 164 2.09 2.68 2.03–3.54 <0.001 
 Left main disease 1,100 66 6.00 7.99 5.70–11.22 <0.001 
Left ventricular 
ejection fraction 
      
 <30% 783 48 6.13 18.90 12.63–28.28 <0.001 
 30%–50% 5,488 82 1.49 4.39 3.08–6.25 <0.001 
 >50% 14,521 50 0.34 1.00 Ref.  
 Clinically 
Contraindicated 
3,989 197 4.94 15.04 11.00–20.55 <0.001 
CCS class IV 
angina 
      
 No 7,395 17 0.23 1.00 Ref.  
 Yes 16,364 361 2.21 9.79 6.02–15.94 <0.001 
NYHA dyspnoea 
≥ 3 or congestive 
heart failure 
      
 No 25,570 311 1.22 1.00 Ref.  
 Yes 776 95 12.24 11.33 8.89–14.43 <0.0001 
Indication for 
procedure 
      
 Stable Angina 8,426 18 0.21 1.00 Ref.  
 STEMI Ongoing 2,253 168 7.46 37.64 23.09–61.34 <0.001 
 STEMI Recurrent 1,216 23 1.89 9.01 4.85–16.74 <0.001 
 Other ACS 14,440 196 1.36 5.75 3.13–10.55 <0.001 
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Category 
Number of 
patients 
Number 
of deaths
30-Day 
mortality 
rate (%) 
Odds 
ratio 
95% 
Confidence 
intervals 
P 
Hemodynamically 
unstable prior to 
procedure 
      
 No 26,168 349 1.33 1.00 Ref.  
 Yes 167 56 33.53 37.33 26.62–52.35 <0.001 
Cardiogenic 
shock 
      
 No 26,149 322 1.23 1.00 Ref.  
 Yes 186 83 44.62 64.64 47.44–88.07 <0.001 
Anticipated need 
for IABP 
      
 No 26,065 324 1.24 1.00 Ref.  
 Yes 285 82 28.77 32.09 24.28–42.42 <0.001 
Critical 
preprocedural 
state 
      
 No 25,876 261 1.01 1.00 Ref.  
 Yes 474 145 30.59 43.26 34.36–54.47 <0.001 
Treated with 
IIb/IIIa inhibitor 
preprocedure 
      
 No 25,419 376 1.48 1.00 Ref.  
 Yes 931 30 3.22 2.22 1.52–3.24 <0.001 
Lytic therapy 
preprocedure 
      
 No 24,485 358 1.46 1.00 Ref.  
 Yes 1,865 48 2.57 1.78 1.31–2.42 <0.001 
Ongoing dialysis 
or serum 
creatinine >200 
μmol/L 
      
 No 25,641 361 1.41 1.00 Ref.  
 Yes 604 37 6.13 4.57 3.23–6.47 <0.001 
Diabetes mellitus       
 No 20,324 283 1.39 1.00 Ref.  
 Yes 5,924 115 1.94 1.40 1.13–1.75 0.003 
Hypertension       
 No 12,022 207 1.72 1.00 Ref.  
 Yes 14,226 191 1.34 0.78 0.64–0.95 0.013 
Hyperlipidaemia       
 No 10,903 266 2.44 1.00 Ref.  
 Yes 15,345 132 0.86 0.35 0.28–0.43 <0.001 
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Category 
Number of 
patients 
Number 
of deaths
30-Day 
mortality 
rate (%) 
Odds 
ratio 
95% 
Confidence 
intervals 
P 
Peripheral 
vascular disease 
      
 No 24,192 350 1.45 1.00 Ref.  
 Yes 2,056 48 2.33 1.63 1.20–2.21 0.002 
Cerebrovascular 
disease 
      
 No 24,433 343 1.40 1.00 Ref.  
 Yes 1,815 55 3.03 2.20 1.64–2.93 <0.001 
Cigarette smoker       
 No 10,137 225 2.22 1.00 Ref.  
 Yes 4,542 55 1.21 0.54 0.40–0.73 <0.001 
 Exsmoker > 3 
months 
11,569 118 1.02 0.45 0.36–0.57 <0.001 
Previous 
myocardial 
infarction 
      
 No 18,444 274 1.49 1.00 Ref.  
 Yes 7,804 124 1.59 1.07 0.87–1.33 0.531 
Previous PCI       
 No 19,588 313 1.60 1.00 Ref.  
 Yes 6,674 86 1.29 0.80 0.63–1.02 0.075 
Previous CABG       
 No 23,121 345 1.49 1.00 Ref.  
 Yes 3,132 53 1.69 1.14 0.85–1.52 0.3901 
History of chronic 
pulmonary 
disease requiring 
treatment 
      
 No 24,235 348 1.44 1.00 Ref.  
 Yes 2,013 50 2.48 1.75 1.30–2.36 <0.001 
Potentially life-
limiting 
hepatobiliary or 
gastrointestinal 
disease 
      
 No 24,923 368 1.48 1.00 Ref.  
 Yes 1,325 30 2.26 1.55 1.06–2.25 0.023 
Diagnosis of 
malignancy 
      
 No 24,757 372 1.50 1.00 Ref.  
 Yes 1,491 26 1.74 1.16 0.78–1.74 0.460 
Table 3. Baseline Variables in CANADA Score Univariate Analysis. 
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 β Coefficient Adjusted OR 95% Confidence intervals 
Intercept −9.89    
Age (per 10 year increase) 0.39 1.48 1.32 1.65 
Gender 0.23 1.26 0.98 1.61 
Emergency 0.95 2.58 1.87 3.57 
Left main disease 1.09 2.98 2.06 4.29 
Triple-vessel disease 0.45 1.57 1.22 2.02 
LVEF < 30% 1.84 6.27 4.02 9.77 
LVEF 30–50% 0.86 2.36 1.63 3.39 
LVEF Clinically 
Contraindicated 
1.55 4.71 3.33 6.66 
NYHA ≥ 3/CHF 0.82 2.26 1.65 3.10 
Critical preprocedural state 1.97 7.20 5.33 9.74 
STEMI Ongoing 2.00 7.40 4.07 13.46 
STEMI Recurrent 1.43 4.19 2.08 8.43 
Other ACS 1.35 3.87 2.30 6.53 
Dialysis/Creatinine > 200 
μmol/L 0.76 2.13 1.40 3.23 
LVEF, Left ventricular ejection fraction; NYHA, New York Heart Association; CHF, Congestive heart 
failure; STEMI, ST-elevation myocardial infarction; ACS, acute coronary syndrome; Critical 
preprocedural state, Hemodynamically unstable prior to procedure or Cardiogenic shock or 
Anticipated need for IABP. 
Table 4. Predictors of Mortality in the CANADA Score Multivariable Model. 
6. Comparison of risks – Surgical versus percutaneous revascularisation 
Increasingly it has become relevant to select the optimal revascularization strategy for 
patients deemed appropriate for revascularisation by either coronary artery bypass grafting 
or percutaneous intervention. Published studies of coronary anatomy alone have shown to 
predict the need for future revascularisation (Serruys et al, 2009; Sianos et al, 2005), but not 
mortality. The scores derived from an anatomical assessment alone has been shown to have 
only modest correlation to predicted risk using either surgical (logistic EuroSCORE) or 
percutaneous (CANADA Score) risk calculators that incorporate clinical and anatomical 
factors (Hoole & Hamburger, 2011). The same study found comparative risk assessment 
using either logistic EuroSCORE or CANADA Score has good correlation (R=0.80) and 
importantly recognised that patients with high predicted risk for surgery may have higher 
risk for a percutaneous revascularisation strategy (Figure 4). This implies patients declined 
for surgery should not necessarily default to a PCI treatment strategy. It must be noted that 
the definition of risk factors in different models may vary and must be considered when 
applying multiple models to individual patients (Table 5). 
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Fig. 4. Comparison of predicted PCI (CANADA Score) and CABG (EuroSCORE) mortality 
relative to tertiles of subject’s anatomical risk (SYNTAX Score). 
Risk Factor EuroSCORE STS Score CANADA Score 
Age  Per 5 years or part thereof 
over 60 years 
Per 5 years or part 
thereof over 60 years 
Per 10 year 
increase 
Sex  Female Female Female 
Chronic 
pulmonary 
disease  
 
Long-term use of 
bronchodilators or 
steroids for lung disease 
 
Patient required 
pharmacologic therapy 
for the treatment of 
chronic pulmonary 
compromise, or patient 
has a FEV1 <75% of 
predicted value 
 
Extracardiac 
arteriopathy  
 
Any one or more of the 
following: 
claudication, carotid 
occlusion or >50% 
stenosis, previous or 
planned intervention on 
the abdominal aorta, limb 
arteries or carotids 
 
Patient has peripheral 
vascular disease as 
indicated by 
claudication either with 
exertion or rest; 
amputation for arterial 
insufficiency; aorto-iliac 
occlusive disease 
reconstruction; 
peripheral vascular 
bypass surgery, 
angioplasty or stent; 
documented AAA, AAA 
repair, or stent; positive 
non-invasive testing 
documented – or – 
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Risk Factor EuroSCORE STS Score CANADA Score 
Patient has 
cerebrovascular disease, 
documented by any one 
of the following: 
Unresponsive coma >24 
h; CVA (symptoms >72 
h after onset); RIND 
(recovery within 72 h); 
TIA (recovery within 24 
h); or noninvasive 
carotid test with >75% 
occlusion 
Neurological 
dysfunction 
disease 
 
Severely affecting 
ambulation or day to day 
functioning 
 
A central neurologic 
deficit persisting more 
than 24 h 
 
Previous 
cardiac surgery 
 
Requiring opening of the 
pericardium 
Prior cardiac surgical 
operation(s) with or 
without the use of 
cardiopulmonary 
bypass 
 
Serum 
creatinine / 
renal 
insufficiency 
> 200 mmol/l 
preoperatively 
> 200 mmol/l 
preoperatively 
> 200 umol/l or 
dialysis 
Active 
endocarditis  
 
Patient still under 
antibiotic treatment for 
endocarditis at the time of 
surgery 
 
Patient currently under 
antibiotic treatment for 
endocarditis at the time 
of 
surgery 
 
Critical 
preoperative 
state  
 
Any one of more of the 
following: 
ventricular tachycardia or 
fibrillation or aborted 
sudden death, 
preoperative cardiac 
massage, preoperative 
ventilation before arrival 
in the 
anaesthetic room, 
preoperative 
inotropic support, intra-
aortic balloon 
counterpulsation or 
preoperative acute renal 
Any one or more of the 
following: sustained 
ventricular tachycardia 
or ventricular fibrillation 
requiring cardioversion 
and/or IV amiodarone, 
preoperative inotropic 
support, preoperative 
intra-aortic balloon 
pump, or 
patient required  
cardiopulmonary 
resuscitation within 1 h 
before the start of the 
operative procedure 
Cardiogenic shock 
(a systolic blood 
pressure of <90 
mmHg for at least 
30 min and/or the 
need for 
supportive 
measures to 
maintain a systolic 
blood pressure of 
>90 mmHg, clinical 
evidence of end-
organ 
hypoperfusion) or 
hemodynamic 
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Risk Factor EuroSCORE STS Score CANADA Score 
failure (anuria or oliguria 
<10 ml/ 
h) 
 
instability prior to 
the procedure 
(transient 
hypotension not 
fulfilling the 
definition for 
cardiogenic shock, 
or caused by 
sustained 
arrhythmia) or the 
anticipated need 
for an intra-aortic 
balloon pump. 
Unstable 
angina  
Rest angina requiring iv 
nitrates until arrival in the 
anaesthetic room 
 
Preoperative use of iv 
nitrates 
STEMI on-going, 
STEMI recurrent or 
other ACS 
LV dysfunction Moderate or LVEF 30–
50%; Poor or LVEF ,30% 
 
LVEF 30–50%; LVEF 
<30% 
LVEF 30–50%; 
LVEF <30% or 
LVEF 
contraindicated* 
Recent 
myocardial 
infarction  
< 90 days < 21 days  
Pulmonary 
hypertension  
Systolic PA pressure >60 
mmHg 
Systolic PA pressure >30 
mmHg 
 
Emergency  
 
Carried out on referral 
before the beginning of 
the next working day 
 
Procedure status is 
emergent or salvage. 
Emergent: The patient’s 
clinical status includes 
any of the following. a. 
Ischaemic dysfunction 
(any of the following): 
(1) ongoing ischaemia 
including rest angina 
despite maximal 
medical therapy 
(medical and/or IABP); 
(2) acute evolving 
myocardial infarction 
within 24 h before 
surgery; or (3) 
pulmonary oedema 
requiring intubation. b. 
Mechanical dysfunction 
Procedure has to 
be done without 
delay 
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Risk Factor EuroSCORE STS Score CANADA Score 
(either of the following): 
(1) shock with 
circulatory support; or 
(2) shock without 
circulatory support. 
Salvage: The patient is 
undergoing CPR en route 
to the OR or prior to 
anaesthesia induction 
Other than 
isolated CABG  
Major cardiac procedure 
other than or in addition 
to CABG 
 
Any valve procedure in 
addition to or separate 
from CABG 
 
Surgery on 
thoracic aorta  
For disorder of ascending, 
arch or descending aorta 
 
Aortic 
aneurysm/dissection 
repair 
 
Post-infarct 
septal rupture 
 Ventricular septal defect  
3 vessel disease   Greater than 50% 
lesion in any three 
vessels 
Left main 
disease 
 >= 50% compromise of 
vessel diameter 
preoperatively 
Greater than 50% 
lesion 
NYHA   ≥ 3 
*LVEF contraindicated = comorbid conditions preclude left ventricular contrast angiography 
(significant aortic stenosis (valve area <1.0 cm2), presence of aortic valve prosthesis, impaired renal 
function (serum creatinine >200umol/L), a critical preprocedural clinical state, NYHA IV dyspnoea, 
grossly elevated left ventricular end diastolic pressure (>30 mmHg). 
Table 5. Definition of Risk Factors for Various Risk Calculators. 
7. Conclusion 
Predicting procedural risk enables the correct treatment decisions to be made and allows 
valid informed consent and accurate patient counselling. This is particularly important as 
PCI has become accepted as a viable alternative to established surgical intervention. Early 
assessment of risk with PCI was limited to short term events that ignored important late 
events and prevented direct comparison with surgical risk predication tools. The CANADA 
Score was developed to accurately predict 30 day mortality risk and has been externally 
validated in large North American cohorts demonstrating broad applicability to varied 
patient groups. The CANADA Score confirms that both anatomical and clinical data are 
required to provide accurate and discriminatory 30 day mortality risk prediction and it 
therefore allows comparison with well validated surgical risk prediction models to guide 
optimal revascularisation strategy. Application of the CANADA Score to patients with high 
surgical risk demonstrates the potential for equal or greater risk with a percutaneous 
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strategy and challenges the traditional notion that percutaneous revascularization should be 
a default strategy for these patients. The CANADA Score is available as an on-line calculator 
(www.canadascore.org) (Figure 5) facilitating easy integration into regular clinical practice. 
 
Fig. 5. On-line CANADA Score Calculator. Available at www.canadascore.org 
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